Dhruvitkumar Sutaria

Dhruvitkumar Sutaria


Summary

I’m a Postdoctoral Scientist at University of Florida. I have worked in the pharmacy field for the last 8 years, gaining wide range of research experience in the areas of drug development, molecular biology and cellular engineering.

My research experience can be summarized as follows:
• 8+ years of experience in mammalian cell culture including isolation of primary pancreatic acini cells from both human and mouse models. Experience with protein overexpression and developing transient/stable cell lines
• 8+ years of experience working with different in vivo models. Hands on experience in drug dosing, tissue dissection, sectioning and staining
• 4+ years of experience in genome editing using CRISPR/Cas systems
• 5+ years of proficiency in standard molecular and cellular techniques
• Familiar with PK/PD, Preclinical aspect of drug development

Biotechnology Molecular Biology Oncology Pharmacology Translational Medicine

Work details

Postdoctoral Associate

University of Florida
January 2017
College of Pharmacy, Dept of Pharmaceutics
Job responsibilities includes: Construction of CRISPR Cas9 libraries for microRNA knockout in mammalian cell lines; designing strategies to develop a conditional triple microRNA knockout mouse model. Maintaining CRISPR Cas9 microRNA KO and KrasG12D x miRNA KO bigenic mouse colonies generated during Ph.D. training to perform tumor survival studies.

Graduate Research Assistant

University of Health Sciences
January 2009 - May 2011
College of Pharmacy
Developed solid lipid nanoparticles for anticancer drugs Aspirin, Sulforaphane & Curcumin. Nanoparticles were tested in vitro in pancreatic cancer cell lines through cell cycle analysis, and by performing western blotting to study their effect on oncogenic cell signaling pathways such as Erk1/2, c-Jun, MAPK and NF-ΚB. Drug efficacy studies were conducted to study nanoparticle effects on colon and pancreatic cancer using Sprague-Dawley rat and Syrian golden hamster model respectively. Tissues were harvested from colon and pancreatic tissues to examine aberrant crypt foci (ACF) and pancreatic intraepithelial lesions (PanIN) respectively in nanoparticle treated vs non-treated groups.

Graduate Research Assistant

Ohio State University
September 2011 - December 2016
College of Pharmacy, Dept of Pharmaceutics and Pharmaceutical Chemistry
Thesis title: Investigation of differentially expressed noncoding RNAs in pancreatic ductal adenocarcinoma Performed RNA isolations on pancreatic cancer patient derived tumors, and carried out gene expression profiling using Agilent microarray platform, and validation using qRT-PCR to identify abnormally expressed noncoding RNAs. Designed, cloned, performed RNA in vitro transcription and assisted in microinjecting single guide RNA’s into mouse embryo to develop microRNA knockout mouse models. Pups carrying mutations were identified using several screening methods which included high resolution melt analysis (HRM), restriction fragment length polymorphism (RFLP), Surveyor nuclease assay and TOPO sequencing. CRISPRi and RNAi studies were conducted using sgRNA’s, siRNA, miRNA oligonucleotides to evaluate the phenotypic effects of these abnormally expressed RNA molecules. Elucidated the role of miRNA in acinar-ductal trans-differentiation by isolating and culturing primary acinar cells on 3D collagen-matrigel gel layer. Acute pancreatitis was induced in the knockout mice to further elucidate the effects of Caerulein on maintain pancreas plasticity and phenotype. Studied cell signaling alterations involved within the KO mouse models using molecular techniques such as qPCR, western blotting, IHC and IF. Designed and engineered fusion protein containing microRNA transcript within its intron. MicroRNA was structurally modified to contain TAR RNA hairpin loop that allowed its binding to the fusion protein that contained the TAT peptide. Generated stable HEK293/HEK293T cell-lines by overexpressing the fusion protein to develop engineered exosomes/microvesicles which contains endogenously loaded microRNA oligonucleotide.